Aurobindo Pharma Buyback 2024 vs Cheviot Company Buyback 2024

The Buy-Back is being undertaken, inter-alia, for the following reasons:

1. The buy-back will help the company reward its shareholders and enhance the overall return to shareholders.
2. The buy-back is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time;
3. The buy-back is being implemented through the tender offer route as prescribed under the buyback regulations and would involve the allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved for small shareholders.

The Buy-Back is being undertaken, inter-alia, for the following reasons:

1. The Buy-Back will help the Company to return surplus cash to its shareholders holding ordinary shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders;
2. The Company believes that the reservation for small shareholders would benefit a large number of public shareholders, who would get classified as "small shareholders" as per Regulation 2(i)(n) of the Buy-Back Regulations;
3. The Buy-Back would help in improving return on equity by reducing the share capital base and increasing shareholder's value in the longer term;
4. The Buy-Back gives an option to the shareholders holding ordinary shares of the Company, who can choose to participate and get cash in lieu of ordinary shares to be accepted under the Buy-Back offer or they may choose not to participate and benefit from a resultant increase in their percentage shareholding, post the Buy-Back offer, without additional investment; and
5. The Buy-Back will help the Company in achieving an optimal capital structure.